Evaluation of the anticancer activity of enzymatically synthesized Baccatin III: an intermediate precursor of Taxol®.

ABSTRACT: Baccatin III is an important precursor for the synthesis of clinically important anticancer drug Taxol. Previously, we have characterized a key enzyme of 10-deacetylbaccatin III-10-β-O-acetyltransferase (DBAT) which catalyses the 10-deacetylbaccatin III into baccatin III in taxol biosynthesis. Here, in the present study, we have evaluated and compared the cytotoxic properties of the enzymatically synthesized baccatin III (ESB III) with standard baccatin III in different human cancer cell lines, namely human cervical cancer (HeLa), human lung cancer (A549), human skin cancer (A431) and human liver cancer cells (HepG2). Among the various cancer lines tested, HeLa was more susceptible to ESB III with IC₅₀ of 4.30 µM while IC₅₀ values for A549, A431 and HepG2 range

SUBMITTER: Sah B 

PROVIDER: S-EPMC7544785 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature